KIR3DL1 and acute myeloid leukemia: Importantly, these benefits were achieved without increased GVHD risk, emphasizing the relevance of B-content KIR genotyping in donor selection [40]. Consistently, a study by Bao et al. highlighted that donor KIR B haplotypes with Cen B-specific motifs (Cen B) significantly improved OS and RFS and reduced NRM in standard-risk AML/myelodysplastic syndrome (MDS) patients undergoing unrelated donor HSCT.